What it's for (Indications)
- Formoterol fumarate dihydrate and budesonide inhalation aerosol is indicated for the maintenance treatment of asthma in patients 6 years of age and older.
- It is intended for patients whose asthma is not adequately controlled on an inhaled corticosteroid (ICS) alone or whose disease severity warrants initiation of treatment with both an ICS and a long-acting beta2-adrenergic agonist (LABA).
- Furthermore, this combination medication is also indicated for the maintenance treatment of airflow obstruction and reduction of exacerbations in adult patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and/or emphysema.
- It is crucial to understand that this medication is not indicated for the relief of acute bronchospasm and should not be used as a rescue inhaler for sudden breathing problems.
- Its primary role is chronic disease management.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For asthma, the typical dosage for adults and adolescents 12 years and older is two inhalations, twice daily, approximately 12 hours apart. Common strengths include budesonide/formoterol 80/4.5 mcg or 160/4.5 mcg per actuation. For children aged 6 to 11 years, the generally recommended dosage is two inhalations of 80/4.5 mcg twice daily. For COPD, the usual dosage for adults is two inhalations of 160/4.5 mcg twice daily, approximately 12 hours apart. The maximum recommended daily dose should not be exceeded. It is imperative that patients rinse their mouth with water and spit out the rinse after each dose to minimize the risk of oral candidiasis (thrush). The medication is administered via oral inhalation and consistent daily use, as prescribed, is essential for optimal therapeutic benefit, not on an as-needed basis. |
Safety & Warnings
Common Side Effects
- Common side effects associated with formoterol and budesonide combination therapy may include upper respiratory tract infection, nasopharyngitis, oral candidiasis (thrush), headache, pharyngolaryngeal pain, sinusitis, back pain, and influenza.
- Systemic effects, though less common with inhaled formulations compared to oral corticosteroids, can occur, especially with high doses or prolonged use.
- Serious adverse effects may include pneumonia (particularly in COPD patients), paradoxical bronchospasm (immediate worsening of breathing after inhalation), cardiovascular effects such as palpitations, tachycardia, and arrhythmias, and hypersensitivity reactions.
- Other potential concerns include immunosuppression leading to increased susceptibility to infections, adrenal suppression, reduction in bone mineral density, growth suppression in children, glaucoma, cataracts, hypokalemia, and hyperglycemia.
- Patients should report any new or worsening symptoms to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: Long-acting beta2-adrenergic agonists (LABAs) such as formoterol, a component of this medication, increase the risk of asthma-related death. Data from a large, randomized, placebo-controlled clinical trial involving another LABA (salmeterol) demonstrated an increased risk of asthma-related deaths. This finding is considered a class effect of LABAs, including formoterol. Consequently, this combination product should only be used as additional therapy for patients with asthma who are currently receiving, but are not adequately controlled on, an inhaled corticosteroid (ICS) alone, or whose disease severity warrants initiation of treatment with both an ICS and a LABA. It is not indicated for the relief of acute bronchospasm. Once asthma control is achieved and maintained, the patient's therapy should be assessed at regular intervals and, if appropriate, stepped down (e.g., discontinuation of the LABA component if feasible). This medication should not be used in patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids alone.
- Formoterol and budesonide is not indicated for the relief of acute bronchospasm; a short-acting beta2-agonist should be used for acute symptoms.
- Therapy should not be initiated in patients during rapidly deteriorating or acutely life-threatening episodes of asthma or COPD.
- Localized infections of the mouth and pharynx with Candida albicans can occur; patients should rinse their mouth after inhalation.
- Systemic effects of inhaled corticosteroids, such as adrenal suppression, reductions in bone mineral density, growth suppression in children, and ocular effects (glaucoma, cataracts), are possible, particularly with high doses or prolonged exposure.
- Caution should be exercised in patients with cardiovascular disorders due to the potential for dose-related cardiovascular effects of LABAs, including arrhythmias, tachycardia, and QT prolongation.
- Use with caution in patients with convulsive disorders, thyrotoxicosis, or diabetes mellitus.
- Severe hypersensitivity reactions can occur.
- Discontinue immediately if paradoxical bronchospasm occurs.
- Close monitoring is recommended for patients with a history of tuberculosis, or untreated fungal, bacterial, viral, or parasitic infections.
How it Works (Mechanism of Action)
This combination medication comprises two distinct pharmacological agents with complementary mechanisms of action to address the complex pathophysiology of asthma and COPD. Formoterol is a selective, long-acting beta2-adrenergic agonist (LABA). It acts by stimulating beta2-receptors in the bronchial smooth muscle, leading to relaxation of the smooth muscle and subsequent bronchodilation. This effect helps to improve airflow and reduce symptoms of bronchoconstriction. Formoterol exhibits a rapid onset of action and a prolonged duration, providing bronchodilation for up to 12 hours. Budesonide is a potent synthetic corticosteroid that, when inhaled, exerts anti-inflammatory actions directly within the airways. It reduces inflammation, decreases airway hyperresponsiveness, and inhibits the migration and activity of inflammatory cells. By targeting the underlying inflammatory processes, budesonide helps to reduce the frequency and severity of exacerbations, diminish mucus production, and improve overall lung function. The synergistic action of bronchodilation from formoterol and anti-inflammatory effects from budesonide effectively manages both the acute and chronic components of respiratory diseases.
Commercial Brands (Alternatives)
No other brands found for this formula.